HEWLETT-PACKARD MODEL 5989A MASS SPECTROMETER

惠普 5989A 型质谱仪

• 批准号: 3522094
• 负责人: STEPHEN S HECHT
• 金额: $ 5.5万
• 依托单位: INSTITUTE FOR CANCER PREVENTION
• 依托单位国家: 美国
• 财政年份: 1993
• 资助国家: 美国
• 起止时间: 1993-08-15 至 1994-08-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3522094
• 关键词: DNA damage; adduct; biomedical equipment purchase; biomedical equipment resource; carcinogens; mass spectrometry

Funding is requested for a Hewlett-Packard Model 5989A "MS Engine" mass spectrometer. This equipment will be the centerpiece of a Carcinogen Dosimetry Laboratory to be established at the American Health Foundation. The new laboratory will be dedicated to the quantitation of carcinogen- protein adducts and carcinogen-DNA adducts in humans. The major user group consists of seven scientists funded by NIH and carrying out projects concerned with carcinogen dosimetry. The present instrumentation, a Hewlett-Packard Model 5988A is used for many other projects at the Foundation and cannot possibly accommodate the tremendous volume of samples that will be generated in the ongoing and proposed dosimetry studies. In addition, the MS Engine is a state of the art instrument which has several performance features which are greatly superior to the 5988A. These include higher sensitivity, especially in the critical negative ion chemical ionization mode, an HPLC/MS interface not available on our current instrument, and improved automation and operational features which will greatly facilitate sample analysis. The new technology that will be developed with the MS Engine is expected to lead to major advances in our understanding of causes of human cancer.

Hewlett-Packard型号5989A“MS Engine”MASS申请资金 分光计。这种设备将成为致癌物质的核心 剂量学实验室将在美国健康基金会建立。 新实验室将致力于致癌物质的定量- 人类的蛋白质加合物和致癌物-DNA加合物。主要用户 该小组由七名科学家组成，由美国国立卫生研究院资助并开展项目 与致癌物质剂量学有关。目前的仪器，一个 Hewlett-Packard型号5988A用于许多其他项目 基础，不可能容纳如此巨大的容量 将在正在进行的和建议的剂量测定中生成的样本 学习。此外，MS引擎是最先进的仪器 它具有几个性能特性，这些特性大大优于 5988A。这些包括更高的敏感度，特别是在关键的 负离子化学电离模式，不提供高效液相/质谱仪界面 在我们当前的仪器上，并改进了自动化和操作 这些特征将极大地方便样品分析。新的 预计将与微软引擎一起开发的技术将引领 在我们对人类癌症病因的理解上取得了重大进展。